Three pharmaceutical manufacturers who joined in a venture to create the cancer-relief pill, Tarceva, say their trials show the drug extends the life of cancer patients by as much as one-third and they are looking for FDA approval by early next year. The study of the drug is to be presented in June, but OSI Pharmaceuticals, Genentech and Roche Holdings released preliminary results of the trial they said prove the greater effectiveness of their product.

Full Story:

Related Summaries